What we do Alembic Pharmaceuticals Ltd manufactures and markets generic pharmaceutical products globally, with strong FDA-approved research and manufacturing facilities. |
Founded in 2,010 |
Market share One of India’s leaders in branded generics, with growing international presence especially in the US generic market. |
Problem solved Provides affordable and quality generic medicines, addressing healthcare accessibility and therapeutic needs worldwide. |
Top clients or who we serve Serves pharmacies, hospitals, healthcare providers globally across B2B and B2C segments with branded generics and APIs. |
Key management Chirayu Amin (Chairman & CEO), Pranav Amin (Managing Director), Shaunak Amin (Managing Director), R.K. Baheti (CFO) |
Our journey and innovations Founded in 2010 after pharma demerger; expanded US FDA approvals; acquisitions like Orit Labs; launched oncology and specialty products; JV in dermatology; and global regulatory compliance. |
Where we operate India, USA, Europe, Middle East, Africa, Australia, Latin America, GCC nations with subsidiaries and subsidiaries. |
Top products or what we offer Generic formulations across specialties such as oncology, gynecology, cardiology, dermatology; APIs; animal health products; branded generics in India and US. |
Top brands Azithral (market leading antibiotic), Tellzy (cardiology), Wikoryl (cough & cold), Gestofit (gynecology), Rosave (statins), Althrocin (anti-infectives). |
Raw materials needed Active pharmaceutical ingredients (APIs), excipients, packaging materials. |
Raw materials supplier Pharma API suppliers globally including in-house API manufacturing capabilities. |
Recurring vs cyclical contribution Revenue predominantly recurring with steady approvals and launches maintaining pipeline and global sales. |
Our industry position Strong foothold in branded generics in India, growing US generics market share, with FDA-approved manufacturing sites. |
Financial highlights FY25 Consolidated revenue ₹6672 Cr, Net profit ₹583 Cr, steady growth in branded and international generics segments. |
Geographical revenue split Domestic revenue approx ₹2618 Cr; International revenue approx ₹4053 Cr, majorly from USA and Europe. |
Order book Robust ANDA pipeline with 245 filings, continuous product launches internationally including specialty and oncology products. |
Whats driving growth Regulatory approvals, product launches in US and specialty segments, expanding global footprint, and focused R&D investment. |
Our future plans Expand oncology and specialty products, increase US launches, strengthen supply chain, and grow presence in Latin America and Middle East. |
Our green promise Committed to sustainability through efficient manufacturing, waste management, and CSR initiatives. |
Our people and values Employee-centric culture fostering innovation, diversity, and ethics across global operations with strong governance. |
Key challenges ahead Competitive pricing pressure, regulatory challenges, patent litigations, and global supply chain disruptions. |
Interesting facts First Indian pharma to commercialize certain oncology products in the US. Expanded through strategic acquisitions and JV's. |
Risks and strategy Mitigate regulatory and market risks via compliance, diversified product portfolio, R&D pipeline, and geographical diversification. |
